Welcome to our dedicated page for GenMark news (Ticker: GNMK), a resource for investors and traders seeking the latest updates and insights on GenMark stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GenMark's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GenMark's position in the market.
GenMark Diagnostics reported impressive financial results for Q1 2020, achieving $38.7 million in total revenue, up 80% from Q1 2019. ePlex revenue rose 119%, reaching $34.3 million. Gross margin increased to 42%, compared to 27% last year. The company expanded its global installed base of ePlex analyzers to 581 and increased average annuity per analyzer to $214,000. Recent achievements include receiving Emergency Use Authorization for the ePlex COVID-19 test and securing $749,000 in BARDA funding. The company raised its 2020 revenue guidance to $120 to $130 million.
GenMark Diagnostics (NASDAQ: GNMK) has appointed Scott Mendel as President and CEO, effective immediately. Mendel, who has been interim CEO since February 2020, brings extensive experience from his previous roles as Chief Operating Officer and Chief Financial Officer. Kevin O'Boyle, Chairman of the Board, expressed confidence in Mendel’s leadership capabilities, particularly in navigating challenges and prioritizing the company’s future success. GenMark specializes in multiplex molecular diagnostic solutions aimed at improving patient care and reducing healthcare costs.